Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PBM Psyence Biomedical Ltd

Pre-Mkt 09-02 07:10:20 EDT

4.37

+0.03

+0.69%

盘前4.37

+0.000.00%

04:00 EDT

High4.37	Low4.21	Vol17.58K
Open4.30	D1 Closing4.34	Amplitude3.68%
Mkt Cap16.67M	Tradable Cap4.78M	Total Shares3.81M
T/O75.76K	T/O Rate1.61%	Tradable Shares1.09M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PBM","market":"US","secType":"STK","nameCN":"Psyence Biomedical Ltd","latestPrice":4.37,"timestamp":1788292800000,"preClose":4.34,"halted":0,"volume":17580,"hourTrading":{"tag":"盘前","latestPrice":4.37,"preClose":4.37,"latestTime":"04:00 EDT","volume":53,"amount":231.61,"timestamp":1788336008107,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.006912442396313422,"floatShares":1094600,"shares":3814300,"eps":-12.559563,"marketStatus":"Pre-Mkt","change":0.03,"latestTime":"09-02 07:10:20 EDT","open":4.3,"high":4.37,"low":4.2101,"amount":75759.08499,"amplitude":0.036843,"askPrice":4.74,"askSize":100,"bidPrice":3.7,"bidSize":20,"shortable":3,"etf":0,"ttmEps":-12.559563,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788355800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":4.37,"preHourTrading":{"tag":"盘前","latestPrice":4.37,"preClose":4.37,"latestTime":"04:00 EDT","volume":53,"amount":231.61,"timestamp":1788336008107,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":4.32,"preClose":4.37,"latestTime":"19:40 EDT","volume":2463,"amount":10638.5515,"timestamp":1788306007123,"change":-0.05,"changeRate":-0.011442,"amplitude":0.01373},"volumeRatio":0.5896431975419644},"requestUrl":"/m/hq/s/PBM","defaultTab":"news","newsList":[{"id":"2660960964","title":"NASDAQ Trade Halt Volatility Trading Pause at 12:58 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2660960964","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660960964?lang=en_us&edition=fundamental","pubTime":"2026-08-19 00:58","pubTimestamp":1787072282,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 12:58 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nAQN2MFDX4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651111460","title":"Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2651111460","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651111460?lang=en_us&edition=fundamental","pubTime":"2026-07-13 20:30","pubTimestamp":1783945800,"startTime":"0","endTime":"0","summary":"Companion Animal Health CT-RevitL   Companion Animal Health CT-RevitL, the next-generation laser therapy system for veterinary care.  CT-RevitL launches in the United States, built on a foundation of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/13/3326176/0/en/Enovis-Companion-Animal-Health-Launches-CT-RevitL-the-Next-Generation-Laser-Therapy-System-for-Veterinary-Care.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENOV","PBM","BK4082","LU2065732104.USD","IE0034390439.USD","BK4139","IE00B19Z6F94.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645945077","title":"Psyence Biomedical FY26 net loss widens to about USD 6.89 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2645945077","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645945077?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:02","pubTimestamp":1782158561,"startTime":"0","endTime":"0","summary":"Psyence Biomedical posted a net loss of about USD 6.89 million for fiscal 2026, remaining pre-revenue with no revenue from product sales.R&D expense more than doubled to USD 1.47 million, reflecting accelerated activity in its Phase IIb psilocybin trial in palliative care patients.Professional and consulting fees climbed to USD 3.65 million, while the company recorded a USD 1.5 million net settlement expense tied to the KAOS Group dispute.Cash rose to USD 7.49 million, lifting working capital to USD 8.49 million; an Australian R&D cash rebate of USD 292,247 was received.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data G","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL1Fjv6r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641145232","title":"A Look At Cigna Group’s Valuation As Analysts Clash Over PBM Transition And Spending Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2641145232","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641145232?lang=en_us&edition=fundamental","pubTime":"2026-06-05 21:31","pubTimestamp":1780666270,"startTime":"0","endTime":"0","summary":"Mixed analyst views put Cigna Group (CI) in focus\nRecent analyst actions on Cigna Group (CI), including a downgrade tied to its pharmacy benefit manager transition and spending plans, along with a more constructive view from another firm, have pushed the stock back onto investor watchlists.\nSee our latest analysis for Cigna Group.\nCigna Group shares have been volatile, with a 3-month share price return of 3.33% and a 1-year total shareholder return that declined 7.76%. This suggests that...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/172899-main-header/1756254126085","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/172899-main-header/1756254126085"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/a-look-at-cigna-groups-valuation-as-analysts-clash-over-pbm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-ci/cigna-group/news/a-look-at-cigna-groups-valuation-as-analysts-clash-over-pbm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1059921491.USD","BK4588","IE00B19Z3581.USD","LU0058720904.USD","BK4139","BK4196","PBM","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","CI","IE0002270589.USD","BK4585","LU0289739699.SGD","LU0868494617.USD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640926451","title":"Launch One Acquisition names Daniel Clifford Rogers audit committee chair after Stack resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2640926451","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640926451?lang=en_us&edition=fundamental","pubTime":"2026-06-03 05:16","pubTimestamp":1780434968,"startTime":"0","endTime":"0","summary":"Launch One Acquisition appointed Daniel Clifford Rogers to its board on June 2, 2026, naming him audit committee chair.Rogers is a consulting CFO focused on fintech, financial services, SaaS; previously CFO at Newcourt Acquisition Corp and Papaya Growth.Dr. Risa Stack resigned from the board, stepping down as audit committee chair and compensation committee member; no disputes were cited.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Launch One Acquisition Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL7DKpCM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LPAA","PBM","PPYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635705244","title":"Psyence BioMed targets U.S. push for GMP ibogaine research, manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635705244","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635705244?lang=en_us&edition=fundamental","pubTime":"2026-05-16 13:17","pubTimestamp":1778908643,"startTime":"0","endTime":"0","summary":"Psyence BioMed launched a U.S. strategic engagement initiative aimed at supporting regulated ibogaine research, with an emphasis on GMP manufacturing and supply readiness.Planning centers on scaling GMP-compliant production capacity to supply future clinical programs, supported by its investment in PsyLabs.Targets include building an ethically sourced, sustainable, traceable ibogaine supply chain designed to support future development and commercialization pathways.Efforts are positioned to align with potential U.S. policy actions that could expand or accelerate authorized scientific and clinical research into ibogaine.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260516:nNDL5Y3L5f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635087475","title":"Psyence Biomed Announces U.S. Strategic Engagement Initiative Focused on Gmp Ibogaine Research and Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635087475","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635087475?lang=en_us&edition=fundamental","pubTime":"2026-05-15 21:15","pubTimestamp":1778850900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nTUA1MKY3L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633095176","title":"Press Release: Omada Health Reports First Quarter 2026 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2633095176","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633095176?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:03","pubTimestamp":1778184180,"startTime":"0","endTime":"0","summary":"Revenue up 42% Year over Year; Total Members Surpass One Million;Expanded Channels Now Include All Three of the Nation's Leading PBMs. SAN FRANCISCO, May 07, 2026  -- Omada Health, Inc. , the virtual between-visit healthcare provider, today reported financial results for the first quarter ended March 31, 2026.-- Total Members: 1.02 million Total Members at the end of Q1, up 51% year. over year, reinforcing Omada's role as an integrated, multi-condition. -- Revenue: $78 million in the first quarter, up 42% year over year.-- Omada joined Optum Rx's Weight Engage portfolio to help employers expand. responsible, clinically supported access to GLP--1 and other. employers a way to provide medication management alongside the clinical. already covering GLP--1s strengthen their approach and offers others a. responsible, clinically guided path to begin coverage of GLP-1s. Omada. now has relationships with the nation's three leading PBMs, who serve. most commercially insured lives and processed 8","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMDA","BK4139","BK4196","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631586086","title":"Health Insurer Cigna Tops Estimates. Why the Stock Is Gaining. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2631586086","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631586086?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:21","pubTimestamp":1777555260,"startTime":"0","endTime":"0","summary":"Cigna was trading modestly higher after the health insurer beat first-quarter profit estimates and slightly raised guidance. The stock remains a \"show-me\" story but that might be enough to keep it moving up.Cigna reported earnings per share of $7.79 for the first quarter, up from $6.74 a year ago. EPS beat Wall Street consensus estimates for $7.60. Cigna raised profit guidance slightly for 2026, expecting at least $30.35 in EPS.Quarterly revenue landed at $68.5 billion, up from $65.5 billion the same period last year. That figure also beat a consensus estimate of $66.3 billion.\"Our strong first quarter results were driven by disciplined execution, deliberate portfolio shaping and a continued focus on targeted innovation,\" CEO David Cordani said in a press release.Cigna is a work in progress, though. The company announced a big shift to its pharmacy benefit manager  business last fall, planning to go \"rebate free.\" The move came in response to criticism over PBMs' role in drug pricing a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002270589.USD","LU0058720904.USD","BK4196","BK4139","BK4588","IE00B19Z3B42.SGD","BK4585","LU1261432733.SGD","LU0289739699.SGD","CI","IE00B19Z3581.USD","LU1059921491.USD","LU0868494617.USD","IE00BSNM7G36.USD","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631522910","title":"Cigna's Earnings Could Show It Has Cleared Away PBM Surprises -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2631522910","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631522910?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:39","pubTimestamp":1777498740,"startTime":"0","endTime":"0","summary":"The Cigna Group elicited plenty of questions from Wall Street analysts when it announced a big shift to its pharmacy benefits business model last fall, by planning to go \"rebate free.\" But heading into its first-quarter earnings results on Thursday, the company may find it has done enough heavy lifting to explain the change.That's in large part because, in February, Cigna's Express Scripts was the first of three major pharmacy-benefit managers, known as PBMs, to reach a settlement agreement with the Federal Trade Commission over insulin pricing litigation. No liability was admitted.The settlement terms reflected the previously announced rebate-free model and helped Wall Street make better sense of the transition to a new way of generating revenue in a significant business line.\"We don't expect too many surprises with CI's 1Q26 earnings print, with likely inline cost trends / MLR on pricing cushions and updates on the progress so far with the company's rebate-free PBM model flip,\" said ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631755518","title":"Amarin Reports 2026 First Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2631755518","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631755518?lang=en_us&edition=fundamental","pubTime":"2026-04-29 19:00","pubTimestamp":1777460400,"startTime":"0","endTime":"0","summary":"Total Revenue Increased Led by Higher International Sales  Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global M","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3283604/18362/en/Amarin-Reports-2026-First-Quarter-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","BK4139","IPE","PBM","TG","BK4153","BK4090","BK4082","CV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629828897","title":"Psyence amends amalgamation agreement with GoldCoast Resource Corp","url":"https://stock-news.laohu8.com/highlight/detail?id=2629828897","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629828897?lang=en_us&edition=fundamental","pubTime":"2026-04-24 14:05","pubTimestamp":1777010739,"startTime":"0","endTime":"0","summary":"Psyence entered an amendment dated April 13, 2026 to its amalgamation agreement signed Nov. 21, 2025 with GoldCoast Resource.Transaction would combine GoldCoast with Psyence Therapeutics, a Psyence subsidiary, with Psyence continuing as resulting issuer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Group Inc. published the original content used to generate this news brief on April 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260424:nNDL35NpyB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GORO","PBM","BK4139","BK4017"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629195833","title":"Psyence BioMed doses first patient in Phase IIb NPX-5 adjustment disorder trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629195833","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629195833?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:09","pubTimestamp":1776942576,"startTime":"0","endTime":"0","summary":"Psyence BioMed began dosing patients in Phase IIb trial of NPX-5, a 25 mg nature-derived psilocybin candidate, for adjustment disorder in cancer patients receiving palliative care.No results have been presented; trial is expected to generate safety and efficacy data in a future readout.Study aims to assess whether NPX-5 can reduce psychological distress while remaining tolerable in this patient group.Randomized, double-blind, three-arm design is running across five clinical sites in Australia.Program supports Psyence BioMed strategy to build vertically integrated psychedelic drug development platform spanning manufacturing, clinical execution, and supply.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nNDL13r3Gc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2210149790.SGD","BK4112","IE00BN0W2W23.USD","BK4139","PBM","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4588","NDAQ","BK4585","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629382468","title":"Psyence Biomed Initiates Patient Dosing in Phase Iib Trial Evaluating Npx-5 for Adjustment Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2629382468","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629382468?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:00","pubTimestamp":1776942001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nTUAPVPGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629000541","title":"Press Release: Samsung Epis Holdings Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2629000541","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629000541?lang=en_us&edition=fundamental","pubTime":"2026-04-23 14:54","pubTimestamp":1776927240,"startTime":"0","endTime":"0","summary":"--  Samsung Bioepis recorded Q1'26 revenue of KRW 454.9 billion and. Samsung Epis Holdings , an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026.\"Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio,\" said Kyung-Ah Kim, President and Chief Executive Officer  of Samsung Epis Holdings. \"We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10 anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.\". On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KRW 454.9 billion with an operating profit of KRW 144.0 billion. Revenue and opera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","BK4231","BK4581","BK4588","BK4099","BK4555","BK4139","BK4585","PPA","ADC","03160","IEMG","BK4080","CEO","PBM","BK4604","EMXC","TM","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629504590","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2629504590","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629504590?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:58","pubTimestamp":1776859121,"startTime":"0","endTime":"0","summary":"Psyence Biomedical  shares were down 15% in Wednesday premarket activity, extending Tuesday's loss.Target Hospitality  stock was 9.3% lower, a day after the company said selling shareholders priced a secondary offering of 7 million shares at $14 per share, for about $98 million in gross proceeds.Calix  stock was 9% lower, after Northland Securities downgraded the company to market perform from outperform and lowered its price target to $52 from $75.TE Connectivity  shares were down 5.5% after the company reported lower-than-expected fiscal Q2 net sales.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1868836914.USD","LU1721428933.USD","LU0312595415.SGD","LU0302445910.USD","LU0347712357.USD","LU0640476718.USD","IE0034235188.USD","LU1868837300.USD","BK4139","IE00B19Z9Z06.USD","LU0689626769.HKD","LU1983260115.SGD","TH","BK4145","CALX","LU0061475181.USD","BK4588","PBM","GB00BDT5M118.USD","LU1868836757.USD","BK4020","LU2413666426.HKD","LU2360107325.USD","TEL","LU1939255532.USD","LU1868837136.USD","LU0130518102.USD","LU0390134368.USD","IE00B894F039.SGD","LU2275660780.HKD","LU2298064838.USD","LU1861219969.SGD","IE00BZ9MQY76.HKD","LU0130103400.USD","IE00BZ199S13.USD","BK4580","LU1201861165.SGD","IE0004086264.USD","LU2106854487.HKD","LU2413666699.HKD","LU1280957306.USD","LU1868836591.USD","LU0096364046.USD","LU2023250504.SGD","LU2238339852.HKD","BK4142","LU2023250843.SGD","LU1974910355.USD","LU1917777945.USD","LU0124676726.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629305962","title":"EXPLAINER-What to know about psychedelic therapies cited by Trump","url":"https://stock-news.laohu8.com/highlight/detail?id=2629305962","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629305962?lang=en_us&edition=fundamental","pubTime":"2026-04-22 01:08","pubTimestamp":1776791303,"startTime":"0","endTime":"0","summary":"April 21  - U.S. President Donald Trump this week signed an executive order directing health regulators to speed reviews of psychedelic treatments and increase federal funding for research into their use in response to advocates for the drug ibogaine including influential podcaster Joe Rogan.Presently almost all psychedelic drugs in the United States are considered Schedule I controlled substances, in the same class as heroin or ecstasy, meaning they are deemed to have no medical use and high risk for abuse.Several treatments derived from psychedelic compounds are being tested by drugmakers. Here is what is known about these treatments: WHAT ARE THE DRUGS BEING TESTED FOR?Psychedelic treatments work primarily by activating proteins on the surface of nerve cells that regulate the brain's ability to reorganize, form new connections, and repair damaged circuits. Unlike traditional psychiatric drugs that may be taken at home on a daily basis, these treatments are usually administered by me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nL1N4130XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2430703251.USD","IE00BVYPNW00.USD","LU1778281490.HKD","ATAI","LU1935042991.SGD","BK4007","LU0234570918.USD","LU1914381329.SGD","IE00BKVL7J92.USD","IE00B4R5TH58.HKD","IE00BDGV0183.EUR","LU0787776722.HKD","CMPS","IE0002270589.USD","LU0058720904.USD","LU1074936037.SGD","LU0124676726.USD","LU0210528500.USD","LU0882574055.USD","LU2471134796.USD","LU0114720955.EUR","LU1057294990.SGD","SG9999002224.SGD","LU2471134879.HKD","JNJ","IE00BFTCPJ56.SGD","LU1506573853.SGD","LU2112291526.USD","FLHLF","BK4532","LU2750360641.GBP","LU2129689514.USD","PBM","SGXZ57979304.SGD","LU1032955483.USD","LU1244550577.SGD","BK4581","LU0053666078.USD","LU0345769631.USD","LU2487616109.SGD","LU1121112475.USD","LU1066051811.HKD","BK4559","LU1732799900.SGD","IE000BZT7R73.USD","LU1894683348.USD","BK4592","LU2430703178.SGD","BK4139","LU2505996681.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628721979","title":"PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2628721979","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628721979?lang=en_us&edition=fundamental","pubTime":"2026-04-20 22:33","pubTimestamp":1776695580,"startTime":"0","endTime":"0","summary":"Psyence Biomedical (NASDAQ: PBM) stock is surging Monday on a broad psychedelic rally and a company-specific ibogaine supply catalyst.","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/20/Financial-Graph-With-Uptrend-Line-Techno.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/20/Financial-Graph-With-Uptrend-Line-Techno.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/04/51915395/pbm-jumps-on-trump-psychedelic-push-ibogaine-supply-story","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/04/51915395/pbm-jumps-on-trump-psychedelic-push-ibogaine-supply-story","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628445907","title":"Psychedelic Pharmaceutical Companies' Shares Rise Following Executive Order","url":"https://stock-news.laohu8.com/highlight/detail?id=2628445907","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628445907?lang=en_us&edition=fundamental","pubTime":"2026-04-20 18:39","pubTimestamp":1776681540,"startTime":"0","endTime":"0","summary":"Shares of several pharmaceutical companies were higher after President Trump signed an executive order aimed at accelerating research, development and access to psychedelic medicines for the treatment of mental illnesses.Definium Therapeutics' stock was up 15%, at $26.03, in premarket trading Monday. Shares of Compass Pathways rose 32%, to $8.78, while shares of Psyence Biomedical jumped 76%, to $13.37.The companies all released statements supporting the executive action.\"We applaud the administration's recognition that psychedelic medicines may represent meaningful new treatment options for patients,\" Definium Chief Executive Rob Barrow said, noting the company will advance a comprehensive clinical development program of its potential treatment for generalized anxiety disorder and major depressive disorder.Compass--which separately said Saturday it is conducting some of the largest, most robust classic psychedelic studies to date--noted it is actively working with the Food and Drug Ad","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","PBM","CMPS","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628132789","title":"Psyence Biomedical Ltd trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2628132789","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628132789?lang=en_us&edition=fundamental","pubTime":"2026-04-18 03:12","pubTimestamp":1776453121,"startTime":"0","endTime":"0","summary":"15:06 EDT Psyence Biomedical (PBM) Ltd trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mark...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psyence-biomedical-ltd-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psyence-biomedical-ltd-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PBM"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacificbooker.bc.ca","stockEarnings":[{"period":"1week","weight":0.0234},{"period":"1month","weight":0.3785},{"period":"3month","weight":0.1063},{"period":"6month","weight":0.707},{"period":"1year","weight":-0.7512},{"period":"ytd","weight":-0.072}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.01},{"period":"6month","weight":0.1181},{"period":"1year","weight":0.181},{"period":"ytd","weight":0.1171}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.237918},{"month":2,"riseRate":0.4,"avgChangeRate":-0.252579},{"month":3,"riseRate":0.6,"avgChangeRate":0.107838},{"month":4,"riseRate":0.6,"avgChangeRate":0.247702},{"month":5,"riseRate":0.4,"avgChangeRate":-0.036399},{"month":6,"riseRate":0.6,"avgChangeRate":-0.15148},{"month":7,"riseRate":0.8,"avgChangeRate":0.19189},{"month":8,"riseRate":0.6,"avgChangeRate":-0.071106},{"month":9,"riseRate":0.8,"avgChangeRate":-0.121482},{"month":10,"riseRate":0.25,"avgChangeRate":-0.079288},{"month":11,"riseRate":0.25,"avgChangeRate":-0.211015},{"month":12,"riseRate":0.25,"avgChangeRate":-0.267978}],"exchange":"NASDAQ","name":"Psyence Biomedical Ltd","nameEN":"Psyence Biomedical Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Psyence Biomedical Ltd,PBM,Psyence Biomedical Ltd股票,Psyence Biomedical Ltd股票老虎,Psyence Biomedical Ltd股票老虎国际,Psyence Biomedical Ltd行情,Psyence Biomedical Ltd股票行情,Psyence Biomedical Ltd股价,Psyence Biomedical Ltd股市,Psyence Biomedical Ltd股票价格,Psyence Biomedical Ltd股票交易,Psyence Biomedical Ltd股票购买,Psyence Biomedical Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}